Thermo Fisher Scientific Inc. (TMO)
Stay Ahead of the Game With Thermo Fisher (TMO) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Thermo Fisher (TMO) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific And Its Real Value
Thermo Fisher Scientific shows strong fundamentals, consistent earnings growth, and solid financial health, making it a viable long-term investment. TMO's recent product expansion, including the breakthrough Krios 5 Cryo-TEM technology, is expected to drive future growth and support earnings. Valuation metrics indicate TMO is currently undervalued.
Is it Worth Retaining Thermo Fisher Stock in Your Portfolio Now?
TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels.
Thermo Fisher's New Deal With CZ Imaging Institute May Boost Its Stock
TMO and CZ Imaging Institute to collaborate on further understanding of human cells.
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab
Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis.
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
Thermo Fisher Scientific's Q4'24 and FY'24 results exceeded expectations, with revenue and profitability growing, positioning it for a potential 12% IRR long-term. Strong capital allocation, including $4.6 billion returned to shareholders and strategic acquisitions, supports Thermo Fisher's growth and undervalued stock potential. Despite weak guidance, Thermo Fisher's leadership in life sciences and pharma, along with expected 11% CAGR earnings growth, indicates a solid long-term outlook.
Billionaire Investor Buys Stocks Despite Trump's ‘Unconventional Approach'
Daniel Loeb is a brilliant billionaire investor who's invested in all sorts of market environments.
Thermo Fisher Scientific Inc. (TMO) TD Cowen 45th Annual Health Care Conference - (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) TD Cowen 45th Annual Health Care Conference Call March 3, 2025 9:10 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Well, welcome to the 45th Annual TD Cowen Healthcare Conference.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Thermo Fisher Stock Surges as Medical Device Maker's Results Top Estimates
Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
